Last reviewed · How we verify
NCT07272434
Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell)
Phase 3 trial testing Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) in Respiratory Syncytial Virus (RSV) in 25,000 participants. Currently enrolling.
31 July 2026
Quick facts
| Lead sponsor | MAXVAX Biotechnology Limited Liability Company |
|---|---|
| Phase | Phase 3 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 25,000 |
| Start date | 22 October 2025 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 December 2028 |
| Sites | 8 locations across China |
Drugs / interventions tested
- Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell) — full drug profile →
- Placebo (Saline solution)
Conditions studied
- Respiratory Syncytial Virus (RSV) — all drugs for Respiratory Syncytial Virus (RSV) →
Sponsor
MAXVAX Biotechnology Limited Liability Company — full company profile →
Who can join
60 and older, any sex, with Respiratory Syncytial Virus (RSV). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study will evaluate the efficacy of the Recombinant RSV vaccine(CHO cell) vaccine in preventing lower respiratory tract diseases(LRTD) caused by RSV in adults≥ 60 years of following a single dose of the RSV vaccine(CHO cell) vaccine .This study will also assess if the vaccine is safe and induces an immune response.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07272434
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Respiratory Syncytial Virus (RSV)
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT06851806 — Study of Palivizumab in Children With High Risk of Severe Respiratory Syncytial Virus (RSV) Disease · NA · recruiting
- NCT07249320 — Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants · active not recruiting
- NCT07106918 — A Clinical Trial of SIBP-A16 Injection in Healthy Adults · EARLY_PHASE1 · recruiting
- NCT07122661 — STudy of Real World vaccinE Effectiveness of maTernal RSVpreF vaccinatiON Against Respiratory Syncytial Virus (RSV) in H · active not recruiting
Other MAXVAX Biotechnology Limited Liability Company trials
Trials by the same sponsor.
- NCT07492706 — Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adul · Phase 1 · not yet recruiting
- NCT07293065 — A Phase III Clinical Trial to Evaluate Long-Term Protective Efficacy of Recombinant Zoster Vaccine (CHO Cell) · Phase 3 · active not recruiting
- NCT06654700 — Phase III Clinical Trial of Lot-to-lot Consistency of Recombinant Herpes Zoster Vaccine (CHO Cell). · Phase 3 · not yet recruiting
- NCT06642558 — Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above · Phase 1, PHASE2 · active not recruiting
- NCT05856084 — Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07272434 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by MAXVAX Biotechnology Limited Liability Company
- Last refreshed: 9 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07272434.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing